近年来出现的聚腺苷二磷酸核糖聚合酶 [poly(ADP-ribose)polymerase,PARP] 抑制剂(PARP inhibitor,PARPi)为新型的靶向治疗药物之一,已经被应用于治疗包括乳腺癌在内的多种恶性肿瘤,并且已获得许多显著的效果,成为相关肿瘤研究的热点之一。 PARPi 的上市状况 PARPi 主要分为...
通过抑制DNA修复产生DNA损伤,增加肿瘤突变负荷,成为更具识别性的免疫治疗靶点。 《TherapeuticPotential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors》刊登于Frontiers in Oncology肿瘤学前沿杂志中,详述阐明了PARP抑制和免疫联...
TPS1113 Phase II trial of a PARP inhibitor in somatic BRCA mutant metastatic breast cancer. 2020 ASCO.
通过抑制DNA修复产生DNA损伤,增加肿瘤突变负荷,成为更具识别性的免疫治疗靶点。 《TherapeuticPotential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors》刊登于Frontiers in Oncology肿瘤学前沿杂志中,详述阐明了PARP抑制和免疫联合治疗在改善实体肿瘤患者预后方面的前景,总结早期研究成果并展望进行中的研究,...
[2]Cruz C, Castroviejo-Bermejo M, Gutierrez-Enriquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, Bonache S, et al. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol 2018;29:1203-1210. ...
[19] Isakoff S J, Overmoyer B, Tung N M, et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer [J]. J Clin Oncol, 2010, 28(15s): 1019. 作者:春风健康海外就医购药服务机构总编 - 卑弥呼 ...
[2] AstraZeneca eyes a safer PARP inhibitor, with nearly 50% response in advanced breast cancer patients: #AACR24. Retrieved April 8, 2024, from https://endpts.com/astrazeneca-eyes-a-safer-parp-inhibitor-with-nearly-50-response-in-advanced-breast-cancer-patients-aacr24/...
对于存在HR修复功能异常的肿瘤,PARP抑制剂(PARP inhibitor,PARPi)通过抑制PARP酶活性和增加PARP-DNA复合物的形成,导致肿瘤细胞DNA损伤修复障碍和促发肿瘤细胞凋亡。 卵巢癌(ovarian cancer)是死亡率最高的妇科恶性肿瘤。肿瘤细胞减灭术以及术后辅以铂类为基础的联合化疗是其标准的传统治疗方法,术后无肉眼残留病变或者...
[2] AstraZeneca eyes a safer PARP inhibitor, with nearly 50% response in advanced breast cancer patients: #AACR24. Retrieved April 8, 2024, from https://endpts.com/astrazeneca-eyes-a-safer-parp-inhibitor-with-nearly-50-response-in-advanced-breast-cancer-patients-aacr24/ ...
[2]Cruz C, Castroviejo-Bermejo M, Gutierrez-Enriquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, Bonache S, et al. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol 2018;29:1203-1210. ...